Pulse corticosteroid therapy in the treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis: Case report and review

被引:3
作者
Lai, Kuan-Chang [2 ]
Hsiao, Yi-Han [1 ]
Chen, San-Chi [3 ]
机构
[1] Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan
[2] Taipei Vet Gen Hosp, Dept Med, Taipei, Taiwan
[3] Taipei Vet Gen Hosp, Ctr Immunooncol, Dept Oncol, Div Med Oncol, Taipei, Taiwan
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
Pulse corticosteroid therapy; steroid-refractory; immune checkpoint inhibitors; pneumonitis; immune-related adverse event; nivolumab;
D O I
10.3389/fimmu.2022.994064
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Immune checkpoint inhibitors (ICIs) have demonstrated promising therapeutic outcomes in treating a variety of malignancies, but immune-related adverse events (irAE) may develop. Among all the irAE, immune-related pneumonitis was relatively common and life-threatening. High-dose corticosteroid was recommended for the initial management, but a part of patients developed steroid-refractory pneumonitis. Other immunosuppressants were recommended, but the optimal treatment is still controversial. Here, we report two cases of steroid-refractory immune-related pneumonitis who were successfully treated with pulse corticosteroid therapy. Case 1 was hepatocellular carcinoma treated with nivolumab for 5 months. She developed acute respiratory distress syndrome due to grade 4 immune-related pneumonitis that was refractory to intravenous methylprednisolone 2 mg/kg/day treatment. Methylprednisolone 500 mg for 3 days followed by 2 mg/kg/day steroid as maintenance therapy was given. Subsequently, her pneumonitis was regressed, and the endotracheal tube was successfully removed on day 9 after the start of pulse therapy. Case 2 presented with grade 4 immune-related pneumonitis in spite the use of methylprednisolone 1 mg/kg for his skin rash. Pulse corticosteroid therapy was prescribed, then his pneumonitis was completely regressed on day 12. In this report, we demonstrated the potential role of pulse corticosteroid therapy for steroid-refractory pneumonitis.
引用
收藏
页数:5
相关论文
共 12 条
  • [1] Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
    Balaji, Aanika
    Hsu, Melinda
    Lin, Cheng Ting
    Feliciano, Josephine
    Marrone, Kristen
    Brahmer, Julie R.
    Forde, Patrick M.
    Hann, Christine
    Zheng, Lei
    Lee, Valerie
    Illei, Peter B.
    Danoff, Sonye K.
    Suresh, Karthik
    Naidoo, Jarushka
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (01)
  • [2] Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
    Beattie, Jason
    Rizvi, Hira
    Fuentes, Paige
    Luo, Jia
    Schoenfeld, Adam
    Lin, I-Hsin
    Postow, Michael
    Callahan, Margaret
    Voss, Martin H.
    Shah, Neil J.
    Warner, Allison Betof
    Chawla, Mohit
    Hellmann, Matthew D.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (02)
  • [3] Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
    Brahmer, Julie R.
    Abu-Sbeih, Hamzah
    Ascierto, Paolo Antonio
    Brufsky, Jill
    Cappelli, Laura C.
    Cortazar, Frank B.
    Gerber, David E.
    Hamad, Lamya
    Hansen, Eric
    Johnson, Douglas B.
    Lacouture, Mario E.
    Masters, Gregory A.
    Naidoo, Jarushka
    Nanni, Michele
    Perales, Miguel-Angel
    Puzanov, Igor
    Santomasso, Bianca D.
    Shanbhag, Satish P.
    Sharma, Rajeev
    Skondra, Dimitra
    Sosman, Jeffrey A.
    Turner, Michelle
    Ernstoff, Marc S.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (06)
  • [4] Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids
    Condon, Marie B.
    Ashby, Damien
    Pepper, Ruth J.
    Cook, H. Terence
    Levy, Jeremy B.
    Griffith, Megan
    Cairns, Tom D.
    Lightstone, Liz
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (08) : 1280 - 1286
  • [5] The safety of pulse corticosteroid therapy-Systematic review and meta-analysis
    Edel, Yonatan
    Avni, Tomer
    Shepshelovich, Daniel
    Reich, Shelley
    Rozen-Zvi, Benaya
    Elbaz, Michal
    Leibovici, Leonard
    Molad, Yair
    Gafter-Gvili, Anat
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2020, 50 (03) : 534 - 545
  • [6] Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors
    Makarious, D.
    Horwood, K.
    Coward, J. I. G.
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 82 : 128 - 136
  • [7] Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy Single Center Experience of Management and Drug Rechallenge
    Manohar, Sandhya
    Ghamrawi, Ranine
    Chengappa, Madhuri
    Goksu, Busra N. Bacik
    Kottschade, Lisa
    Finnes, Heidi
    Dronca, Roxana
    Leventakos, Konstantinos
    Herrmann, Joerg
    Herrmann, Sandra M.
    [J]. KIDNEY360, 2020, 1 (01): : 16 - 24
  • [8] The Use of Glucocorticoids in Lupus Nephritis: New Pathways for an Old Drug
    Mejia-Vilet, Juan M.
    Ayoub, Isabelle
    [J]. FRONTIERS IN MEDICINE, 2021, 8
  • [9] Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience
    Oleas, Diana
    Bolufer, Monica
    Agraz, Irene
    Felip, Enriqueta
    Munoz, Eva
    Gabaldon, Alejandra
    Bury, Roxana
    Espinel, Eugenia
    Seron, Daniel
    Garcia-Carro, Clara
    Jose Soler, Maria
    [J]. CLINICAL KIDNEY JOURNAL, 2021, 14 (05) : 1364 - 1370
  • [10] A case of cystitis after administration of nivolumab
    Keisuke Ozaki
    Hisaya Takahashi
    Yoshihide Murakami
    Hiroshi Kiyoku
    Hiroomi Kanayama
    [J]. International Cancer Conference Journal, 2017, 6 (4) : 164 - 166